01.02.14
Electromed Inc. received U.S. Food and Drug Administration (FDA) clearance for its SQL device, the company’s next-generation SmartVest airway clearance system.
SQL is an electrically powered precursor device designed to deliver high-frequency chest wall oscillation (HFCWO) to promote airway clearance, improve bronchial drainage and enhance mucus transport under the order of a physician’s prescription. It is prescribed to patients with a wide range of pulmonary-related health conditions including bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, muscular dystrophy and cerebral palsy. HFCWO has been demonstrated to reduce lung infections and reduce healthcare costs associated with recurrent pneumonias, antibiotic use and hospital stays, according to the company.
“SQL solidifies Electromed’s innovation leadership by offering a device that is smaller, quieter and lighter than our previous versions,” said Kathleen Skarvan, Electromed’s CEO. “We designed the SQL to stand apart from the competition with features that our patients and clinicians were asking for. They talked, and we listened. In addition to being significantly smaller, quieter and lighter than our previous versions, some of the features include enhanced ramping, an enhanced pause feature and more user-friendly graphics."
Electromed anticipates that the SQL will be available in the next few months.
“We believe we have the most comfortable and easy-to-use system among leading HFCWO devices, which leads to therapy adherence and better patient outcomes,” Skarvan added.
New Prague, Minn.-based Electromed makes products that provide airway clearance therapy to patients with compromised pulmonary function.
SQL is an electrically powered precursor device designed to deliver high-frequency chest wall oscillation (HFCWO) to promote airway clearance, improve bronchial drainage and enhance mucus transport under the order of a physician’s prescription. It is prescribed to patients with a wide range of pulmonary-related health conditions including bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, muscular dystrophy and cerebral palsy. HFCWO has been demonstrated to reduce lung infections and reduce healthcare costs associated with recurrent pneumonias, antibiotic use and hospital stays, according to the company.
“SQL solidifies Electromed’s innovation leadership by offering a device that is smaller, quieter and lighter than our previous versions,” said Kathleen Skarvan, Electromed’s CEO. “We designed the SQL to stand apart from the competition with features that our patients and clinicians were asking for. They talked, and we listened. In addition to being significantly smaller, quieter and lighter than our previous versions, some of the features include enhanced ramping, an enhanced pause feature and more user-friendly graphics."
Electromed anticipates that the SQL will be available in the next few months.
“We believe we have the most comfortable and easy-to-use system among leading HFCWO devices, which leads to therapy adherence and better patient outcomes,” Skarvan added.
New Prague, Minn.-based Electromed makes products that provide airway clearance therapy to patients with compromised pulmonary function.